TY - JOUR
T1 - Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD
AU - CRIC Study Investigators
AU - Bansal, Nisha
AU - Zelnick, Leila R.
AU - Ballantyne, Christie M.
AU - Chaves, Paulo H.M.
AU - Christenson, Robert H.
AU - Coresh, Josef
AU - deFilippi, Christopher R.
AU - de Lemos, James A.
AU - Daniels, Lori B.
AU - Go, Alan S.
AU - He, Jiang
AU - Hedayati, S. Susan
AU - Matsushita, Kunihiro
AU - Nambi, Vijay
AU - Shlipak, Michael G.
AU - Taliercio, Jonathan J.
AU - Seliger, Stephen L.
AU - Appel, Lawrence J.
AU - Feldman, Harold I.
AU - Lash, James P.
AU - Nelson, Robert G.
AU - Rao, Panduranga S.
AU - Rahman, Mahboob
AU - Shah, Vallabh O.
AU - Townsend, Raymond R.
AU - Unruh, Mark L.
N1 - Funding Information:
In addition to authors Go and He, the CRIC Study Investigators comprise Lawrence J. Appel, MD, MPH, Harold I. Feldman, MD, MSCE, James P. Lash, MD, Robert G. Nelson, MD, MS, PhD, Panduranga S. Rao, MD, Mahboob Rahman, Vallabh O. Shah, MD, MS, PhD, Raymond R. Townsend, MD, and Mark L. Unruh, MD, MS. Nisha Bansal, MD, Leila R. Zelnick, PhD, Christie M. Ballantyne, MD, Paulo H.M. Chaves, MD, PhD, Robert H. Christenson, PhD, Josef Coresh, MD, Christopher R. deFilippi, MD, James A. de Lemos, MD, Lori B. Daniels, MD, Alan S. Go, MD, Jiang He, MD, PhD, S. Susan Hedayati, MD, Kunihiro Matsushita, MD, Vijay Nambi, MD, Michael G. Shlipak, MD, Jonathan J. Taliercio, DO, and Stephen L. Seliger, MD. Research idea and study design: NB, LZ, SS; data acquisition: NB, ASG, JH, SS; data analysis/interpretation: NB, LZ, CB, PC, RC, JC, CdF, JdL, LD, ASG, JH, SH, KM, VN, MS, JT, SS; statistical analysis: NB, LZ, SS. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. This work was supported by NIH grant no. R01 DK103612 (to Dr Bansal). Roche Diagnostics provided partial funding for the NT-proBNP and hsTnT assays. Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003; Johns Hopkins University UL1 TR-000424; University of Maryland GCRC M01 RR-16500; Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433; University of Illinois at Chicago CTSA UL1RR029879; Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036; Kaiser Permanente NIH/NCRR UCSF-CTSI UL1 RR-024131; Department of Internal Medicine, University of New Mexico School of Medicine Albuquerque, NM R01DK119199. The funders had no role in study design, data collection, analysis, reporting, or the decision to submit for publication. The authors declare that they have no relevant financial interests. Received December 28, 2020. Evaluated by 3 external peer reviewers and a statistician, with editorial input from an Acting Editor-in-Chief (Editorial Board Member Manish M. Sood, MD, FRCPC). Accepted in revised form June 3, 2021. The involvement of an Acting Editor-in-Chief to handle the peer-review and decision-making processes was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.
Funding Information:
This work was supported by NIH grant no. R01 DK103612 (to Dr Bansal). Roche Diagnostics provided partial funding for the NT-proBNP and hsTnT assays. Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003; Johns Hopkins University UL1 TR-000424; University of Maryland GCRC M01 RR-16500; Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433; University of Illinois at Chicago CTSA UL1RR029879; Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036; Kaiser Permanente NIH/NCRR UCSF-CTSI UL1 RR-024131; Department of Internal Medicine, University of New Mexico School of Medicine Albuquerque, NM R01DK119199. The funders had no role in study design, data collection, analysis, reporting, or the decision to submit for publication.
Publisher Copyright:
© 2021 National Kidney Foundation, Inc.
PY - 2022/3
Y1 - 2022/3
N2 - Rationale & Objective: The utility of conventional upper reference limits (URL) for N-terminal pro–brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) in chronic kidney disease (CKD) remains debated. We analyzed the distribution of hsTnT and NT-proBNP in people with CKD in ambulatory settings to examine the diagnostic value of conventional URL in this population. Study Design: Observational study. Setting & Participants: We studied participants of the Chronic Renal Insufficiency Cohort (CRIC) with CKD and no self-reported history of cardiovascular disease. Exposure: Estimated glomerular filtration rate (eGFR). Outcome: NT-proBNP and hsTnT at baseline. Analytical Approach: We described the proportion of participants above the conventional URL for NT-proBNP (125 pg/mL) and hsTnT (14 ng/L) overall and by eGFR. We then estimated 99th percentile URL for NT-proBNP and hsTnT. Using quantile regression of the 99th percentile, we modeled the association of eGFR with NT-proBNP and hsTnT. Results: Among 2,312 CKD participants, 40% and 43% had levels of NT-proBNP and hsTnT above the conventional URL, respectively. In those with eGFR < 30 mL/min/1.73 m2, 71% and 68% of participants had concentrations of NT-proBNP and hsTnT above the conventional URL, respectively. Among all CKD participants, the 99th percentile for NT-proBNP was 3,592 (95% CI, 2,470-4,849) pg/mL and for hsTnT it was 126 (95% CI, 100-144) ng/L. Each 15 mL/min/1.73 m2 decrement in eGFR was associated with a ~40% higher threshold for the 99th percentile of NT-proBNP (1.43 [95% CI, 1.21-1.69]) and hsTnT (1.45 [95% CI, 1.31-1.60]). Limitations: Study included ambulatory patients, and we could not test the accuracy of the URL of NT-proBNP and hsTnT in the acute care setting. Conclusions: In this ambulatory CKD population with no self-reported history of cardiovascular disease, a range of 40%-88% of participants had concentrations of NT-proBNP and hsTnT above the conventional URL, depending on eGFR strata. Developing eGFR-specific thresholds for these commonly used cardiac biomarkers in the setting of CKD may improve their utility for evaluation of suspected heart failure and myocardial infarction.
AB - Rationale & Objective: The utility of conventional upper reference limits (URL) for N-terminal pro–brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) in chronic kidney disease (CKD) remains debated. We analyzed the distribution of hsTnT and NT-proBNP in people with CKD in ambulatory settings to examine the diagnostic value of conventional URL in this population. Study Design: Observational study. Setting & Participants: We studied participants of the Chronic Renal Insufficiency Cohort (CRIC) with CKD and no self-reported history of cardiovascular disease. Exposure: Estimated glomerular filtration rate (eGFR). Outcome: NT-proBNP and hsTnT at baseline. Analytical Approach: We described the proportion of participants above the conventional URL for NT-proBNP (125 pg/mL) and hsTnT (14 ng/L) overall and by eGFR. We then estimated 99th percentile URL for NT-proBNP and hsTnT. Using quantile regression of the 99th percentile, we modeled the association of eGFR with NT-proBNP and hsTnT. Results: Among 2,312 CKD participants, 40% and 43% had levels of NT-proBNP and hsTnT above the conventional URL, respectively. In those with eGFR < 30 mL/min/1.73 m2, 71% and 68% of participants had concentrations of NT-proBNP and hsTnT above the conventional URL, respectively. Among all CKD participants, the 99th percentile for NT-proBNP was 3,592 (95% CI, 2,470-4,849) pg/mL and for hsTnT it was 126 (95% CI, 100-144) ng/L. Each 15 mL/min/1.73 m2 decrement in eGFR was associated with a ~40% higher threshold for the 99th percentile of NT-proBNP (1.43 [95% CI, 1.21-1.69]) and hsTnT (1.45 [95% CI, 1.31-1.60]). Limitations: Study included ambulatory patients, and we could not test the accuracy of the URL of NT-proBNP and hsTnT in the acute care setting. Conclusions: In this ambulatory CKD population with no self-reported history of cardiovascular disease, a range of 40%-88% of participants had concentrations of NT-proBNP and hsTnT above the conventional URL, depending on eGFR strata. Developing eGFR-specific thresholds for these commonly used cardiac biomarkers in the setting of CKD may improve their utility for evaluation of suspected heart failure and myocardial infarction.
KW - Cardiac biomarkers
KW - N-terminal pro–brain natriuretic peptide (NT-proBNP)
KW - cardiovascular disease
KW - chronic kidney disease (CKD)
KW - diagnostic threshold
KW - heart failure (HF)
KW - high-sensitivity cardiac troponin T (hsTnT)
KW - laboratory measurement
KW - myocardial infarction (MI)
KW - troponin
KW - upper limit of normal (ULN)
UR - http://www.scopus.com/inward/record.url?scp=85114744170&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114744170&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2021.06.017
DO - 10.1053/j.ajkd.2021.06.017
M3 - Article
C2 - 34293394
AN - SCOPUS:85114744170
SN - 0272-6386
VL - 79
SP - 383
EP - 392
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3
ER -